Background {#Sec1}
==========

In Canada, cervical cancer represents 1.5% of new cancer diagnoses in women \[[@CR1]\]. There is decreasing incidence of this disease which is likely attributable to thorough optimized screening programs and Human Papilloma Virus (HPV) vaccinations. However, approximately 400 women die annually from cervical cancer in Canada \[[@CR1]\]. The Society of Obstetricians and Gynecologists of Canada (SOGC) 2012 guideline on managing abnormal cervical cytology recommends standard management for cervical dysplasia \[[@CR2]\]. Women diagnosed with High Grade Squamous Intraepithelial Lesion/Cervical Intraepithelial Neoplasia (HSIL/CIN2--3) who are treated with a Loop Electrosurgical Excision Procedure (LEEP) to prevent invasive disease \[[@CR3]\] are currently followed in colposcopy for two visits over 12 months, post-treatment, to assess for completeness of excision. The rate of disease recurrence is approximately 3--4% \[[@CR4], [@CR5]\].

There is limited evidence on the ideal follow-up protocol for women after they have had a LEEP. The current practice --- and recommendation --- in Canada is two negative colposcopy visits, with women undergoing cytology and endocervical curettage, with biopsy if necessary, at 6-month intervals. Alternatively, a negative HPV test with negative cytology at 6-months is considered adequate follow up \[[@CR2]\]. This is based on level II-2 evidence. Currently, a randomized controlled trial is taking place in Canada, assessing the sensitivity of HPV testing at the first post procedure visit versus the traditional two-visit follow up \[[@CR5]\].

In Calgary, HPV testing is not routinely performed in follow-up, and local recurrence rates are not available. It is not uncommon for small, central LEEPs to be combined with peripheral laser ablation of residual dysplastic tissue, theoretically minimizing the volume of cervix excised while preventing disease recurrence. There is a paucity of data on combination treatments. This study aims to quantify the prevalence of disease recurrence (HSIL/CIN 2--3) in the second visit at 12 months, after one negative follow-up visit in this unique demographic and treatment modality.

Methods {#Sec2}
=======

This was a retrospective cohort study. Electronic medical records were accessed from the Tom Baker Cancer Centre's (TBCC) electronic information system, ARIA (ARIA MO Manager v.13.7. Varian Medical Systems, Inc. Palo Alto, USA). REDCap \[[@CR6]\] was used for data collection and tracking. Data was extracted from colposcopy forms, pathology and operative reports by NP and AR. January 2010 served as the initial LEEP data collection point. Sequential charts were accessed and assessed for inclusion criteria. A target of 292 patient charts was established based on a sample size calculation with a frequency of 5% and a 2.5% variance at the 95% confidence level. The last LEEP included in the study occurred in December 2015 in order to allow for sufficient follow up and chart completion.

LEEP procedures in Calgary are done in the outpatient setting with operating room facilities available for patients requiring sedation and anesthetic beyond a paracervical block. Immediately prior to LEEP, colposcopy is performed to identify the transformation zone with Lugol's solution and a LEEP electrode is selected to best fit the targeted tissue to be excised. Laser is used to ablate any residual or peripheral dysplastic appearing tissue, especially with a broad (Type I) transformation zone. An endocervical curettage (ECC) is subsequently performed. In follow up visits, targeted biopsies and ECC are used when clinically appropriate without used of anesthetic.

Inclusion criteria were as follows: patients over the age of 18 with biopsy or endocervical curettage (ECC) proven HSIL/CIN2/3 with LEEP performed between January 2010 and December 2015 at the Tom Baker Cancer Centre in Calgary, Alberta. Patients were excluded if they had prior treatment for cervical cancer or dysplasia, had a concurrent diagnosis such as adenocarcinoma in-situ (AIS), or if records were incomplete due to missing data or loss to follow-up. A CONSORT diagram (Diagram 1) was completed, and STROBE cohort criteria were followed.

Once data collection was complete, the data was analyzed with SAS version 9.3 (SAS Institute Inc., Cary, NC, USA). Descriptive statistics were used to summarize baseline characteristics and follow up details. Frequencies and proportions, along with 95% confidence intervals were calculated for the rates of disease present at the second follow up visit, additional visits, and further LEEPs required. Ethics approval was obtained in 2016 by The Health Research Ethics Board of Alberta Cancer Committee (HREBA.CC-16-0429).

Results {#Sec3}
=======

303 patients were included for data collection. Patients were excluded for the following reasons: inadequate follow up (67), lack of HSIL/CIN2--3 on biopsy or ECC (8), prior treatment (5), concurrent diagnosis of AIS (2). 221 patients were subsequently analyzed.

Baseline characteristics can be found in Table [1](#Tab1){ref-type="table"}. The median age was 32 with a range from 19 to 68. Forty-one percent of the patients were nulligravid, and 53% were nulliparous. Twenty-four percent of patients identified as smokers. All patients had either a positive cervical biopsy (for CIN 2/3), a positive ECC, or both. The majority of cases did not receive concurrent laser treatment at the time of LEEP (66%) and the majority of patients had pathologic margins free of disease (54%). Table 1Baseline CharacteristicsCharacteristicFrequency (%) or median (IQR)Age in years, median (IQR)32 (11) Range 19 to 68Gravidity 090 (40.7%) 140 (18.1%) 2+91 (41.2%)Parity 0117 (52.9%) 141 (18.6%) 2+63 (28.5%)Smoker Yes54 (24.4%) No167 (75.6%)Pre-LEEP biopsy Negative10 (4.5%) LSIL9 (4.1%) HSIL/SIL unqualified^a^155 (70.1%) Not done47 (21.3%)Pre-LEEP ECC Negative64 (29.0%) LSIL4 (1.8%) HSIL/SIL unqualified^a^138 (62.4%) Not done15 (6.8%)Laser Use Yes76 (34.4%) No145 (65.6%)Margins Margins free120 (54.3%) Endocervical margins43 (19.5%) Ectocervical margins35 (15.8%) Both23 (10.4%)ECC at LEEP Negative178 (80.5%) LSIL3 (1.4%) HSIL23 (10.4%) Inconclusive13 (5.9%) Not done4 (1.8%)^a^SIL unqualified includes 'cannot rule out HSIL'

First follow-up data can be found in Table [2](#Tab2){ref-type="table"}. These patients were all seen between four and eight months post-LEEP. There was no CIN 2 or 3 detected at the first follow up visit which may be a reflection of the low rate of biopsy at first follow-up visit. Biopsy was done for dysplastic appearing tissue and ECC was performed if the transformation zone was unable to be visualized. Cytology was positive for HSIL in one patient (0.5%) but was limited to low grade dysplasia (LSIL/CIN 1) on biopsy and required no retreatment to date. Table 2First (6-month) follow-up dataCharacteristicFrequency (%)First follow-up impression Negative181 (81.9%) LSIL11 (5.0%) HSIL3 (1.4%) Not documented26 (11.8%)First follow-up cytology Negative171 (77.4%) ASCUS/LSIL13 (5.9%) ASC-H/HSIL1 (0.5%) Indeterminate36 (16.3%)First follow-up biopsy Negative16 (7.2%) CIN I or \>3 (1.4%) Not done202 (91.4%)First follow-up ECC Negative174 (78.7%) LSIL or \>7 (3.2%) Not done40 (18.1%)

Second follow-up data can be found in Table [3](#Tab3){ref-type="table"}. At the second follow up, 178 (80.5%) patients had negative cytology. Ninety-three percent of patients did not require biopsy at the second follow up visit. Seventy-two percent of patients had a negative ECC at this time. Fifteen percent of patients did not undergo an ECC, leaving 5% who had LSIL, and almost 3% who had HSIL. The remaining 6% were not classified due to inadequate tissue sampling. Table 3Second (12-month) follow-up dataCharacteristicFrequency (%)Second follow-up cytology Negative178 (80.5%) ASCUS/LSIL15 (6.8%) ASC-H/HSIL6 (2.7%) Indeterminate22 (9.9%)Second follow-up biopsy Negative8 (3.6%) CIN 1/LSIL5 (2.3%) CIN2--3/HSIL2 (0.9%) Not done206 (93.2%)Second follow-up ECC Negative158 (71.5%) LSIL11 (5.0%) HSIL6 (2.7%) Indeterminate13 (5.9%) Not done33 (14.9%)Second follow-up impression Negative180 (81.5%) LSIL11 (5.0%) HSIL2 (0.9%) Not documented28 (12.7%)Second follow-up outcome Repeat colpo28 (12.7%) HSIL/repeat LEEP7 (3.2%) No disease, discharge from colpo186 (84.2%)Further visits None -- Pt discharged190 (86.0%) Observation -- no treatment to date23 (10.4%) Further treatment for HSIL7 (3.2%) Further treatment for persistent LSIL1 (0.5%)

Based on the second colposcopy visit, the vast majority (86%) of patients were discharged from colposcopy. Seven percent of patients were diagnosed with LSIL and were seen for an additional (third) colposcopy follow-up. Six percent did not have LSIL or HSIL but were seen for an additional visit, although the current protocol would result in discharge with pathology [\<]{.ul} LSIL. 3.2% (7 patients) were diagnosed with HSIL and underwent a second LEEP.

This study found that 14.0% of patients (*n* = 31) required further follow up based on findings at the second colposcopy follow up visit. Table [4](#Tab4){ref-type="table"} details final outcome data. Twenty-three of these patients (10.4%) required no additional treatment during the study interval and were discharged from colposcopy. Follow up, annual cervical screening is then completed by primary care or the referring gynecologist. Seven of the 31 patients who required additional visits underwent a second LEEP for treatment of HSIL/CIN2--3, for a retreatment rate of 3.2%. One additional patient underwent a second LEEP for persistent LSIL. Table 4Treatment outcomes based on second (12-month) follow-up visitOutcomeFrequency (%) exact 95% confidence intervalsPositive for disease at second follow-up visit^b^7 (3.2%)1.3 to 6.4%Re-treatment^b^8 (3.6%)1.6 to 6.7%Further visits31 (14.0%)9.7 to 19.3%^a^HSIL/CIN2--3 on biopsy or ECC, out of all 221 patients^b^Includes one patient who underwent repeat LEEP for persistent LSIL

Discussion {#Sec4}
==========

Our results demonstrate a retreatment rate of 3.2% due to high grade cervical dysplasia after undergoing a primary LEEP and having no evidence of disease at first follow-up colposcopy. One tenth of patients underwent a third colposcopy assessment and did not require further treatment or colposcopy follow up. This data is a reflection of the local practice in Calgary, Alberta, Canada, where laser is used in combination with LEEP in approximately one-third (34%) of cases.

Of all patients who underwent a primary LEEP for high grade cervical dysplasia (CIN 2--3), the vast majority (86%) were discharged from colposcopic with cytologic follow-up, having two 'negative' post-LEEP colposcopic and cytologic assessments. Of the remaining patients, most (10.4%) were discharged from colposcopic follow up to annual cytology after the third, post-LEEP assessment. The remaining 3.2% were re-treated with a second LEEP to excise CIN 2 or 3. If all patients were discharged from colposcopy follow-up after a single negative post-LEEP assessment, necessary re-treatment would not have been achieved in a timely manner.

The rationale for use of laser ablation at the time of LEEP concerns itself with mitigating obstetrical adverse outcomes, such as pre-term labour and cervical insufficiency. By potentially limiting the volume of cervix excised, use of a smaller LEEP specimen followed by laser ablation may adequately treat superficial dysplasia while sparing cervical parenchyma. Kyrgiou et al. demonstrated a dose related response to increasing depth of tissue excision although patients with untreated CIN and pregnancies prior to excision demonstrated an increased rate of preterm birth, above the baseline population \[[@CR7]\]. A depth of 10 mm or less should be targeted for women of reproductive age but does increase the rate of recurrence in women over the age of 35 \[[@CR8], [@CR9]\].

The majority of published literature on rates of treatment success and recurrence rates of CIN 2--3 indicate variable numbers to what has been documented in the Calgary Zone \[[@CR10]--[@CR15]\]. Methodology within each study was variable with regard to type of treatment, number of visits, follow-up intervals, colposcopic assessment versus cytology only, use of laser in addition to LEEP, as well as patient demographics, including HPV immunization protocols. Rates have been documented from 1.4 to 26.3% \[[@CR16], [@CR17]\]. This large discrepancy can be attributed to the heterogeneous methodology in the literature.

Santesso et al., in a meta-analysis of randomized control trials assessing outcomes between different modalities, documented a recurrence rate of CIN 2/3 of 5.3% on review of over 8000 patients \[[@CR18]\]. These included cold-knife conization, LEEP, and cryotherapy but none of the literature assessed LEEP with the addition of laser ablation. An elevated rate of pre-term labor was associated with all modalities, but most notably with cold knife conization suggesting that a smaller tissue specimen may be advantageous for patients who may conceive a pregnancy.

The rate of CIN 2--3 at 12-months (3.2%) may be lower than other studies due to the combination of LEEP and laser use if a wider treatment field is targeted, the lack of HPV testing in follow up (false negative cytology, ECC, or biopsy), as HPV testing has been shown to have higher sensitivity and specificity compared to cytology alone \[[@CR19]\]. Our study also excluded patients who had CIN2--3 documented on biopsy within six months of primary LEEP. Had these cases been included, the re-treatment rate would have been higher, similar to Wu, Ju, and Cecchini's publications \[[@CR20]--[@CR22]\].

The rate of dysplasia that we detected may be elevated relative to Prendville's study due to their smaller sample size (102 vs. 221 in our study), consistent with a skewed population sample \[[@CR23]\]. Papoutsis followed patients with cytology only which also may have been responsible for producing an artificially low rate of high-grade dysplasia \[[@CR9]\].

There are several notable strengths and limitations of our study. The health information system, ARIA, and the use of REDCap data collection software allowed for thorough record keeping and referencing. Although there were limited patient numbers, the collected and complete data facilitated accurate analysis. Another strength of our study is the minimal operator variation between colposcopists. The LEEPs included in this Calgary based study were performed by five Gynecologic Oncologists and follow-up was completed by all five members of the group. This enhances the internal validity and, in turn, may hinder the external validity as protocols vary by center.

The use of laser in combination with the LEEP may affect disease rates for multiple reasons. First, tissue destruction with a laser may treat lesions not excised, or where margins are positive. This may result in a higher treatment success than if laser was not used in combination with the LEEP. Second, the availability and use of laser may result in a smaller specimen, and in turn, positive margin status. This was mitigated by excluding patients who had evidence of disease present at the first, six-month follow-up, but may still affect the results of our study. Disease recurrence beyond 12 months with LEEP and laser ablation remains to be documented.

A power calculation resulted in a target of 292 patients. After exclusions, our sample size reached 221 data points. A larger data set would have increased the reliability and precision of our estimate of the retreatment rate. This concern was balanced with the option of including LEEPs performed in the Women's Health Clinic in Calgary[1](#Fn1){ref-type="fn"}; however, variations in providers, charting, and data access made this option less feasible and would have subjected our data set to more variability.

A final limiting factor for this study is the lack of documentation of HPV vaccination status or HPV genotyping, which is not currently part of the standard of care in Canada. HPV vaccinations were first offered to girls in grade 5 (aged 10/11) in Alberta in 2008. Correlating HPV vaccination status and genotyping with disease and recurrence rates may provide useful prognostic information and will be an informative relationship to investigate.

Patients should be made aware of the importance of follow up after undergoing a LEEP and counselled appropriately. Until a protocol with better outcomes is established, this standard of care can be used to predict HSIL/CIN2--3 disease rates at one year after treatment, and more accurately, in a setting which utilizes laser ablation with approximately one third of LEEPs. Future research may assess the cost effectiveness of a second visit, knowing approximately 10% of patients have a third assessment which does not result in additional dysplasia detection. Future research may also seek to assess the long-term rates of disease recurrence when LEEP is combined with user of laser vaporization.

Conclusion {#Sec5}
==========

In conclusion, in women undergoing a primary LEEP for CIN 2--3, dysplasia requiring further treatment is observed in 3.2% of the population at 12-months post-treatment, after having one negative, 6-month colposcopic assessment. This finding supports the use of a two-negative colposcopy follow-up protocol for this patient population, especially when HPV testing is not widely available and remains to be proven to be superior.
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Laser is not used in the out-patient setting in the Women's Health Clinic. The exclusion of patients from this setting may result in data skewness.
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